Alzheimer's drug may stop disease if used before symptoms develop

August 1, 2018 by Fariss Samarrai, University of Virginia
The reddish-blue mouse neurons in this image have reentered the cell cycle after exposure to amyloid beta oligomers, and thus are primed for death. Credit: Erin Kodis and George Bloom

About 50 percent of people who reach the age of 85 will develop Alzheimer's disease. Most will die within about five years of exhibiting the hallmark symptoms of the disease – severe memory loss and a precipitous decline in cognitive function.

But the molecular processes that lead to the will have begun years earlier.

Currently, there are no known ways to prevent the disease or to stop its progression once it has begun. But research at the University of Virginia offers new understanding of how the disease develops at the molecular level, long before extensive neuronal damage occurs and symptoms show up.

Additionally, the researchers have found that an FDA-approved drug, memantine, currently used only for alleviating the symptoms of moderate-to-severe Alzheimer's disease, might be used to prevent or slow the progression of the disease if used before symptoms appear. The research also offers, based on extensive experimentation, a hypothesis as to why this might work.

The findings are published currently online in the journal Alzheimer's & Dementia.

"Based on what we've learned so far, it is my opinion that we will never be able to cure Alzheimer's disease by treating patients once they become symptomatic," said George Bloom, a UVA professor and chair of the Department of Biology, who oversaw the study in his lab. "The best hope for conquering this disease is to first recognize patients who are at risk, and begin treating them prophylactically with new drugs and perhaps lifestyle adjustments that would reduce the rate at which the silent phase of the disease progresses.

"Ideally, we would prevent it from starting in the first place."

As Alzheimer's disease begins, there is a lengthy period of time, perhaps a decade or longer, when affected by the disease attempt to divide, possibly as a way to compensate for the death of neurons. This is unusual in that most neurons develop prenatally and then never divide again. But in Alzheimer's the cells make the attempt, and then die.

"It's been estimated that as much as 90 percent of neuron death that occurs in the Alzheimer's brain follows this reentry process, which is an abnormal attempt to divide," Bloom said. "By the end of the course of the disease, the patient will have lost about 30 percent of the neurons in the frontal lobes of the brain."

Erin Kodis, a former Ph.D. student in Bloom's lab and now a scientific editor at AlphaBioCom, hypothesized that excess calcium entering neurons through calcium channels on their surface drive those neurons back into the cell cycle. This occurs before a chain of events that ultimately produce the plaques found in the Alzheimer's brain. Several experiments by Kodis ultimately proved her theory correct.

The building blocks of the plaques are a protein called amyloid beta oligomers. Kodis found that when neurons are exposed to toxic amyloid oligomers, the channel, called the NMDA receptor, opens, thus allowing the calcium flow that drives back into the cell cycle.

Memantine blocks cell cycle reentry by closing the NMDA receptor, Kodis found.

"The experiments suggest that memantine might have potent disease-modifying properties if it could be administered to patients long before they have become symptomatic and diagnosed with Alzheimer's disease," Bloom said. "Perhaps this could prevent the disease or slow its progression long enough that the average age of symptom onset could be significantly later, if it happens at all."

Side effects of the drug appear to be infrequent and modest.

Bloom said potential patients would need to be screened for Alzheimer's biomarkers years before symptoms appear. Selected patients then would need to be treated with memantine, possibly for life, in hopes of stopping the disease from ever developing, or further developing.

"I don't want to raise false hopes," Bloom said, but "if this idea of using memantine as a prophylactic pans out, it will be because we now understand that calcium is one of the agents that gets the disease started, and we may be able to stop or slow the process if done very early."

Bloom currently is working with colleagues at the UVA School of Medicine to design a clinical trial to investigate the feasibility of using memantine as an early intervention.

Explore further: New mechanism by which Alzheimer's disease spreads through the brain discovered

More information: Erin J. Kodis et al, N-methyl-D-aspartate receptor–mediated calcium influx connects amyloid-β oligomers to ectopic neuronal cell cycle reentry in Alzheimer's disease, Alzheimer's & Dementia (2018). DOI: 10.1016/j.jalz.2018.05.017 , dx.doi.org/10.1016/j.jalz.2018.05.017

Related Stories

New mechanism by which Alzheimer's disease spreads through the brain discovered

June 14, 2018
The waste-management system of the cell appears to play an important role in the spread of Alzheimer's disease in the brain. A new study has focused on small, membrane-covered droplets known as exosomes. It was long believed ...

Overlapping mechanisms in HIV cognitive disorders and Alzheimer's disease

April 9, 2018
A protein involved in Alzheimer's disease (AD) may be a promising target for treating neurological disorders in human immunodeficiency virus (HIV) patients, suggests a study published in JNeurosci of rat neurons and brain ...

Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

May 22, 2018
During the past decade, researchers have identified new ways to detect the earliest biological signs of Alzheimer's disease. These early signs, which are detected by biomarkers, may be present before a person starts to exhibit ...

Antibiotic restores cell communication in brain areas damaged by Alzheimer's disease

November 15, 2016
New research from the Djavad Mowafaghian Centre for Brain Health at UBC has found a way to partially restore brain cell communication around areas damaged by plaques associated with Alzheimer's disease.

Alzheimer's drug may help treat traumatic brain injury

July 21, 2017
Traumatic brain injury (TBI) is a major cause of disability and death globally, but medications have generally failed to benefit patients. A new study found that memantine, a drug that is used to treat dementia associated ...

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 25, 2018
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly ...

Recommended for you

Amyloid pathology transmission in lab mice and historic medical treatments

December 13, 2018
A UCL-led study has confirmed that some vials of a hormone used in discontinued medical treatments contained seeds of a protein implicated in Alzheimer's disease, and are able to seed amyloid pathology in mice.

Study links slowed brainwaves to early signs of dementia

December 13, 2018
To turn back the clock on Alzheimer's disease, many researchers are seeking ways to effectively diagnose the neurodegenerative disorder earlier.

New discoveries predict ability to forecast dementia from single molecule

December 11, 2018
Scientists who recently identified the molecular start of Alzheimer's disease have used that finding to determine that it should be possible to forecast which type of dementia will develop over time—a form of personalized ...

Researchers classify Alzheimer's patients in six subgroups

December 5, 2018
Researchers studying Alzheimer's disease have created an approach to classify patients with Alzheimer's disease, a finding that may open the door for personalized treatments.

Neuroscientists pinpoint genes tied to dementia

December 3, 2018
A UCLA-led research team has identified genetic processes involved in the neurodegeneration that occurs in dementia—an important step on the path toward developing therapies that could slow or halt the course of the disease. ...

Detecting signs of neurodegeneration earlier and more accurately

November 30, 2018
Signs of neurodegenerative diseases, appearing years before the emergence of clinical manifestations, can be detected during the examination of medical samples by means of fluorescence microscopy by using new sensitive and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.